MX385552B - Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia. - Google Patents

Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia.

Info

Publication number
MX385552B
MX385552B MX2019003285A MX2019003285A MX385552B MX 385552 B MX385552 B MX 385552B MX 2019003285 A MX2019003285 A MX 2019003285A MX 2019003285 A MX2019003285 A MX 2019003285A MX 385552 B MX385552 B MX 385552B
Authority
MX
Mexico
Prior art keywords
vitamin
individual
dementia
omega
composition
Prior art date
Application number
MX2019003285A
Other languages
English (en)
Other versions
MX2019003285A (es
Inventor
Claus Rieker
Corina Boschat
Jeroen Antonius Johannes Schmitt
Julie Hudry-Labbe
Yvonne Beata Silber
Original Assignee
Soc Des Produits Nestle S A Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soc Des Produits Nestle S A Star filed Critical Soc Des Produits Nestle S A Star
Publication of MX2019003285A publication Critical patent/MX2019003285A/es
Publication of MX385552B publication Critical patent/MX385552B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para atenuar, tratar o prevenir el envejecimiento cognitivo en un individuo que no tiene demencia incluye administrar al individuo una cantidad terapéuticamente eficaz de una composición que contiene un ácido graso omega-3, un compuesto que libera óxido nítrico y vitamina B12. La composición se administra en una dosis diaria que proporciona de 50 a 500 veces la cantidad diaria recomendada (RDA) de vitamina B12 por día, por ejemplo, aproximadamente 200 veces la RDA de vitamina B12 por día. Opcionalmente, se puede incluir vitamina B6 y/o vitamina B9 en la composición. El método puede lograr un beneficio que es uno o más de disminuir la atrofia cerebral, aumentar o mantener el número de sinapsis, aumentar la fagocitosis de ß-amiloide o disminuir o mantener la neuroinflamación en el individuo no demente. El método puede prevenir la demencia en un individuo en riesgo de padecerla, por ejemplo, un ser humano anciano.
MX2019003285A 2016-09-29 2017-09-29 Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia. MX385552B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662401443P 2016-09-29 2016-09-29
US201762484119P 2017-04-11 2017-04-11
US201762484156P 2017-04-11 2017-04-11
PCT/EP2017/074729 WO2018060395A1 (en) 2016-09-29 2017-09-29 Omega 3 fatty acids, no releasing compound and vitamin b12 as neuroprotectant in patients with no dementia

Publications (2)

Publication Number Publication Date
MX2019003285A MX2019003285A (es) 2019-11-11
MX385552B true MX385552B (es) 2025-03-18

Family

ID=60009613

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019003285A MX385552B (es) 2016-09-29 2017-09-29 Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia.
MX2019002827A MX391435B (es) 2016-09-29 2017-09-29 Acidos grasos omega 3 y colina como neuroprotectores en pacientes sin demencia.
MX2021015377A MX2021015377A (es) 2016-09-29 2019-03-11 Acidos grasos omega 3 y colina como neuroprotectores en pacientes sin demencia.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2019002827A MX391435B (es) 2016-09-29 2017-09-29 Acidos grasos omega 3 y colina como neuroprotectores en pacientes sin demencia.
MX2021015377A MX2021015377A (es) 2016-09-29 2019-03-11 Acidos grasos omega 3 y colina como neuroprotectores en pacientes sin demencia.

Country Status (9)

Country Link
US (2) US11813233B2 (es)
EP (3) EP3518917A1 (es)
JP (4) JP7523905B2 (es)
CN (2) CN109689041A (es)
AU (2) AU2017336292B2 (es)
BR (2) BR112019004041A2 (es)
CA (1) CA3034684A1 (es)
MX (3) MX385552B (es)
WO (2) WO2018060396A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385552B (es) * 2016-09-29 2025-03-18 Soc Des Produits Nestle S A Star Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia.
AU2017408873A1 (en) * 2017-04-11 2019-08-29 Societe Des Produits Nestle S.A. Omega-3 fatty acid and vitamin D levels to identify and attenuate cognitive aging in individuals
WO2018188771A1 (en) 2017-04-11 2018-10-18 Nestec S.A. Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
EP4040992A1 (en) * 2019-12-19 2022-08-17 Société des Produits Nestlé S.A. Compositions and methods for providing a health benefit to a growing animal
WO2022214861A1 (en) * 2021-04-06 2022-10-13 Stellar Biomolecular Research Gmbh A nutraceutical formulation
CN116459264A (zh) * 2023-02-28 2023-07-21 中南民族大学 磷脂酰胆碱在制备用于抗神经性炎症的食品或药品中的应用
IT202300004461A1 (it) * 2023-03-09 2024-09-09 Global Pharmacies Partner S R L In Forma Abbreviata G P P S R L Composizione comprendente trigliceridi a media catena, omega-3 e colina per uso in un metodo di trattamento di declino cognitivo e demenza
WO2025019706A1 (en) * 2023-07-19 2025-01-23 Ahara Corporation Systems and methods for generating a nutrition program

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
HUE031206T2 (en) * 2005-05-23 2017-06-28 Massachusetts Inst Technology Formulations and methods of application containing PUFA
US20080003330A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
WO2009002148A1 (en) 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
NO2194781T3 (es) * 2007-10-04 2018-07-21
MX337760B (es) * 2008-01-04 2016-03-17 Nestec Sa Composiciones que comprenden acidos grasos no saturados y oxido nitrico liberando compuestos y el uso de los mismos para mejorar las funciones cognocitivas y relacionadas.
WO2010078504A1 (en) * 2008-12-31 2010-07-08 Nitromega Corp. Nutraceuticals containing nitro fatty acids
US20120148685A1 (en) 2009-06-10 2012-06-14 Engergy4Life AG Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
US8691775B2 (en) * 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
WO2012091542A1 (en) * 2010-12-28 2012-07-05 N.V. Nutricia Combination of components for the prevention and treatment of frailty
WO2014027882A1 (en) 2012-08-13 2014-02-20 N.V. Nutricia Product and method for supporting uridine homeostasis
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
EP2986123A4 (en) * 2013-03-15 2017-03-22 Buck Institute For Research On Aging Improved cognitive supplements
WO2015060317A1 (ja) * 2013-10-22 2015-04-30 長谷川亨 神経変性疾患の検査方法
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
AU2016281870B2 (en) * 2015-06-22 2020-09-10 Société des Produits Nestlé S.A. Compositions and methods for enhancing neurogenesis in animals
MX385552B (es) * 2016-09-29 2025-03-18 Soc Des Produits Nestle S A Star Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia.

Also Published As

Publication number Publication date
JP2019534853A (ja) 2019-12-05
US20190209601A1 (en) 2019-07-11
AU2017336292A1 (en) 2019-02-21
US11813233B2 (en) 2023-11-14
BR112019004055A2 (pt) 2019-05-21
US10821130B2 (en) 2020-11-03
JP2019530665A (ja) 2019-10-24
AU2017336291B2 (en) 2023-01-12
BR112019004041A2 (pt) 2019-05-28
JP2023011800A (ja) 2023-01-24
EP3518917A1 (en) 2019-08-07
CA3034684A1 (en) 2018-04-05
AU2017336292B2 (en) 2023-08-03
MX2021015377A (es) 2022-03-02
AU2017336291A1 (en) 2019-02-21
JP2025084779A (ja) 2025-06-03
WO2018060395A1 (en) 2018-04-05
MX391435B (es) 2025-03-21
CN109689041A (zh) 2019-04-26
MX2019002827A (es) 2019-07-15
EP3518919A1 (en) 2019-08-07
MX2019003285A (es) 2019-11-11
JP7523905B2 (ja) 2024-07-29
WO2018060396A1 (en) 2018-04-05
CN109661227A (zh) 2019-04-19
CA3034187A1 (en) 2018-04-05
US20200046660A1 (en) 2020-02-13
EP3811938A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
MX385552B (es) Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia.
PH12018502634A1 (en) Topical compositions of apremilast
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
EA201892286A1 (ru) Лекарственные формы с модифицированным высвобождением для снижения злоупотреблений
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l&#39;administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
BR112017022101A2 (pt) composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
CL2019001415A1 (es) Composición para promover la diferenciación de y para proteger las células madre neuronales y método para inducir la regeneración neural utilizando la misma.
EP3581175A4 (en) PREPARATION FOR THE ADMINISTRATION OF A DRUG FOR THE TREATMENT OF MENTAL ILLNESSES OR CENTRAL NERVOUS SYSTEM DISORDERS
CL2019000018A1 (es) Formas sólidas de un estimulador de sgc.
MX2018015112A (es) Composiciones de nanoemulsión de fármacos taxoides, y métodos para su uso para actuar sobre células cancerosas y células madre cancerosas.
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
Morrison Cognitive behaviour therapy for auditory hallucinations without concurrent medication: A single case
FI3426237T3 (fi) Menetelmä aivojen atrofian hoitamiseksi
Tan et al. Possible involvement of l-arginine–nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant-like effect of Wuling mycelia powder in rat
MX2015010594A (es) Esteres de testosterona de cadena larga lipobalanceados para suministro oral.
BR112018067663A2 (pt) compostos derivados de sulfamato, processos para preparação dos mesmos e seus usos
ZA202210027B (en) Compositions of vitamin a palmitate, processes for their preparation, uses and methods comprising them
Fedorova et al. The current views of the treatment of diffuse external otitis
EP4388082A4 (en) IPSC-DERIVED IMMUNE CELLS IN THE PROPHYLAXIS AND TREATMENT OF AGE-ASSOCIATED AND NEURODEGENERATIVE DISEASES
BR112018067674A2 (pt) compostos derivados de carbamato, processos para preparação dos mesmos e seus usos.
BR112018017167A2 (pt) titulação de cebranopadol
EP4284361A4 (en) Novel formulation for treating copper metabolism-associated diseases or disorders
AR102494A1 (es) Métodos para tratar enfermedades oculares

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SOCIETE DES PRODUITS NESTLE S.A.*